10-mg dose of E5501 lipid-based oral ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
63	特発性血小板減少性紫斑病	1

63. 特発性血小板減少性紫斑病

---

臨床試験数 : 391 /  薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01549054 (ClinicalTrials.gov)	January 2012	31/1/2012	A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501	A Single-center, Randomized, Open-label, Two-part Study to Evaluate Bioavailability of Prototype Third-generation Formulations of E5501 Relative to Second-generation Tablet Formulation in Healthy Subjects	Idiopathic Thrombocytopenic Purpura	Drug: 10-mg dose of E5501 2G tablet;Drug: 10-mg dose of E5501 cyclodextrin oral solution;Drug: 10-mg dose of E5501-P21% powder;Drug: 10-mg dose of E5501 lipid-based oral	Eisai Inc.	NULL	Completed	18 Years	55 Years	Both	28	Phase 1	United Kingdom